PSP Research LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA

PSP Research LLC bought a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,084 shares of the company’s stock, valued at approximately $532,000.

Other hedge funds also recently bought and sold shares of the company. Archer Investment Corp acquired a new position in Palvella Therapeutics in the 3rd quarter worth about $28,000. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics in the 3rd quarter worth about $36,000. China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics in the 4th quarter worth about $167,000. Chung Wu Investment Group LLC increased its position in Palvella Therapeutics by 1,200.0% in the 4th quarter. Chung Wu Investment Group LLC now owns 2,600 shares of the company’s stock worth $272,000 after purchasing an additional 2,400 shares during the last quarter. Finally, AlphaQuest LLC acquired a new position in Palvella Therapeutics in the 3rd quarter worth about $164,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Trading Up 4.0%

Shares of PVLA stock opened at $109.20 on Wednesday. The stock has a 50 day moving average of $123.39 and a two-hundred day moving average of $104.88. Palvella Therapeutics, Inc. has a 12 month low of $20.20 and a 12 month high of $151.18. The company has a market capitalization of $1.57 billion, a P/E ratio of -26.19 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Sell-side analysts predict that Palvella Therapeutics, Inc. will post -5.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares in the company, valued at approximately $23,396,375. This represents a 2.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 20.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

PVLA has been the topic of a number of analyst reports. HC Wainwright increased their price objective on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. BTIG Research increased their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Truist Financial set a $210.00 price objective on Palvella Therapeutics in a report on Tuesday, February 24th. Finally, Stifel Nicolaus set a $250.00 price objective on Palvella Therapeutics in a report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $199.53.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.